An amphipathic undecapeptide with all D-amino acids shows promising activity against colistin-resistant strains of Acinetobacter baumannii and a dual mode of action

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 592-599

  Oddo, Alberto ^a   Thomsen, Thomas T ^a   Kjelstrup, Susanne ^a   Gorey, Ciara ^a   Franzyk, Henrik ^a   Frimodt Møller, Niels ^b   Løbner Olesen, Anders ^a   Hansen, Paul R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPATHIC UNDECAPEPTIDE; BP100 DERIVATIVE; BP143 PEPTIDE; BP157 PEPTIDE; BP201 PEPTIDE; BP202 PEPTIDE; BP203 PEPTIDE; BP204 PEPTIDE; BP205 PEPTIDE; BP206 PEPTIDE; BP207 PEPTIDE; BP208 PEPTIDE; BP209 PEPTIDE; BP210 PEPTIDE; BP211 PEPTIDE; BP212 PEPTIDE; BP213 PEPTIDE; BP214 PEPTIDE; COLISTIN; DEXTRO AMINO ACID; PEPTIDE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; RW BP100 PEPTIDE; UNCLASSIFIED DRUG; ACYLTRANSFERASE; AMIDASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; LYSYL-LYSYL-LEUCYL-PHENYLALANYL-LYSYL-LYSYL-ISOLEUCYL-LEUCYL-LYSYL-TYROSYL-LEUCINAMIDE; OLIGOPEPTIDE; PMRA PROTEIN, BACTERIA; PMRB PROTEIN, BACTERIA; TRANSCRIPTION FACTOR;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; EC50; GENE MUTATION; IN VITRO STUDY; LPXC GENE; LPXD GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PMRA GENE; PMRB GENE; PRIORITY JOURNAL; AMINO ACID SEQUENCE; DRUG EFFECTS; ERYTHROCYTE; GENE EXPRESSION; GENETICS; HEMOLYSIS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR GENETICS; MUTATION; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACINETOBACTER BAUMANNII; ACYLTRANSFERASES; AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLISTIN; DRUG RESISTANCE, BACTERIAL; ERYTHROCYTES; GENE EXPRESSION; HEMOLYSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; OLIGOPEPTIDES; SOLID-PHASE SYNTHESIS TECHNIQUES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 84957922744     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01966-15     Document Type: Article

References (36)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471-3484. http://dx.doi.org/10.1128/AAC.01464-06.
2. Hawley JS, Murray CK, Jorgensen JH. 2008. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52:351-352. http://dx.doi.org/10.1128/AAC.00766-07.
3. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:2946-2950. http://dx.doi.org/10.1128/AAC.00103-06.
4. Abbott I, Cerqueira GM, Bhuiyan S, Peleg AY. 2013. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther 11:395-409. http://dx.doi.org/10.1586/eri.13.21.
5. Vila J, Pachon J. 2012. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother 13:2319-2336. http://dx.doi.org/10.1517/14656566.2012.729820.
6. Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL, Jacobs F. 2006. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 25:257-260. http://dx.doi.org/10.1007/s10096-006-0123-1.
7. Valencia R, Arroyo LA, Conde M, Aldana JM, Torres MJ, Fernandez-Cuenca F, Garnacho-Montero J, Cisneros JM, Ortiz C, Pachon J, Aznar J. 2009. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 30:257-263. http://dx.doi.org/10.1086/595977.
8. López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J. 2011. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis 204:1147-1148. http://dx.doi.org/10.1093/infdis/jir476.
9. Vaara M. 2013. Novel derivatives of polymyxins. J Antimicrob Chemother 68:1213-1219. http://dx.doi.org/10.1093/jac/dkt039.
10. Tsubery H, Ofek I, Cohen S, Fridkin M. 2000. The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide. Biochemistry 39:11837-11844. http://dx.doi.org/10.1021/bi000386q.
11. Beceiro A, Moreno A, Fernández N, Vallejo JA, Aranda J, Adler B, Harper M, Boyce JD, Bou G. 2014. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 58:518-526. http://dx.doi.org/10.1128/AAC.01597-13.
12. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 55:3370-3379. http://dx.doi.org/10.1128/AAC.00079-11.
13. Moffatt JH, Harper M, Harrison P, Hale JDF, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971-4977. http://dx.doi.org/10.1128/AAC.00834-10.
14. Velkov T, Thompson PE, Nation RL, Li J. 2010. Structure-activity relationships of polymyxin antibiotics. J Med Chem 53:1898-1916. http://dx.doi.org/10.1021/jm900999h.
15. Saugar JM, Alarcón T, López-Hernández S, López-Brea M, Andreu D, Rivas L. 2002. Activities of polymyxin B and cecropin A-melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents Chemother 46:875-878. http://dx.doi.org/10.1128/AAC.46.3.875-878.2002.
16. Saugar JM, Rodríguez-Hernández MJ, de la Torre BG, Pachón-Ibañez ME, Fernández-Reyes M, Andreu D, Pachón J, Rivas L. 2006. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother 50:1251-1256. http://dx.doi.org/10.1128/AAC.50.4.1251-1256.2006.
17. Badosa E, Ferre R, Planas M, Feliu L, Besalu E, Cabrefiga J, Bardaji E, Montesinos E. 2007. A library of linear undecapeptides with bactericidal activity against phytopathogenic bacteria. Peptides 28:2276-2285. http://dx.doi.org/10.1016/j.peptides.2007.09.010.
18. Güell I, Cabrefiga J, Badosa E, Ferre R, Talleda M, Bardají E, Planas M, Feliu L, Montesinos E. 2011. Improvement of the efficacy of linear undecapeptides against plant-pathogenic bacteria by incorporation of D-amino acids. Appl Environ Microbiol 77:2667-2675. http://dx.doi.org/10.1128/AEM.02759-10.
19. Torcato IM, Huang Y-H, Franquelim HG, Gaspar D, Craik DJ, Castanho MARB, Troeira Henriques S. 2013. Design and characterization of novel antimicrobial peptides, R-BP100 and RW-BP100, with activity against Gram-negative and Gram-positive bacteria. Biochim Biophys Acta 1828:944-955. http://dx.doi.org/10.1016/j.bbamem.2012.12.002.
20. Zuckermann RN, Kerr JM, Kent SBH, Moos WH. 1992. Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. J Am Chem Soc 114:10646-10647. http://dx.doi.org/10.1021/ja00052a076.
21. Fernandez-Cuenca F, Pascual A, Ribera A, Vila J, Bou G, Cisneros JM, Rodriguez-Bano J, Pachon J, Martinez-Martinez L. 2004. Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000). Enferm Infecc Microbiol Clin 22:267-271.
22. García-Quintanilla M, Pulido MR, Moreno-Martínez P, Martín-Peña R, López-Rojas R, Pachón J, McConnell MJ. 2014. Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrob Agents Chemother 58:2972-2975. http://dx.doi.org/10.1128/AAC.02642-13.
23. Fernandez-Reyes M, Rodriguez-Falcon M, Chiva C, Pachon J, Andreu D, Rivas L. 2009. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 9:1632-1645. http://dx.doi.org/10.1002/pmic.200800434.
24. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5:48-56. http://dx.doi.org/10.1038/nrmicro1557.
25. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. http://dx.doi.org/10.1016/S0140-6736(97)07324-8.
26. Clements JM, Coignard F, Johnson I, Chandler S, Palan S, Waller A, Wijkmans J, Hunter MG. 2002. Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother 46:1793-1799. http://dx.doi.org/10.1128/AAC.46.6.1793-1799.2002.
27. Evans BA, Hamouda A, Amyes SG. 2013. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des 19:223-238. http://dx.doi.org/10.2174/138161213804070285.
28. Soon RL, Nation RL, Hartley PG, Larson I, Li J. 2009. Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant Acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment. Antimicrob Agents Chemother 53:4979-4986. http://dx.doi.org/10.1128/AAC.00497-09.
29. Jacobs AC, Sayood K, Olmsted SB, Blanchard CE, Hinrichs S, Russell D, Dunman PM. 2012. Characterization of the Acinetobacter baumannii growth phase-dependent and serum responsive transcriptomes. FEMS Immunol Med Microbiol 64:403-412. http://dx.doi.org/10.1111/j.1574-695X.2011.00926.x.
30. Fiester SE, Actis LA. 2013. Stress responses in the opportunistic pathogen Acinetobacter baumannii. Future Microbiol 8:353-365. http://dx.doi.org/10.2217/fmb.12.150.
31. fepE gene involved in the O-antigen synthesis of Salmonella enterica serovar Typhimurium. Microbiology 157:2515-2521. http://dx.doi.org/10.1099/mic.0.050088-0.
32. Soon RL, Nation RL, Cockram S, Moffatt JH, Harper M, Adler B, Boyce JD, Larson I, Li J. 2011. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J Antimicrob Chemother 66:126-133. http://dx.doi.org/10.1093/jac/dkq422.
33. Wade D, Boman A, Wahlin B, Drain CM, Andreu D, Boman HG, Merrifield RB. 1990. All-D amino acid-containing channel-forming antibiotic peptides. Proc Natl Acad Sci U S A 87:4761-4765. http://dx.doi.org/10.1073/pnas.87.12.4761.
34. Bulet P, Urge L, Ohresser S, Hetru C, Otvos L, Jr. 1996. Enlarged scale chemical synthesis and range of activity of drosocin, an O-glycosylated antibacterial peptide of Drosophila. Eur J Biochem 238:64-69. http://dx.doi.org/10.1111/j.1432-1033.1996.0064q.x.
35. Liu L, Fang Y, Wu J. 2013. Flexibility is a mechanical determinant of antimicrobial activity for amphipathic cationic α-helical antimicrobial peptides. Biochim Biophys Acta 1828:2479-2486. http://dx.doi.org/10.1016/j.bbamem.2013.06.017.
36. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM. 2005. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25:1325-1331. http://dx.doi.org/10.1161/01.ATV.0000165694.39518.95.